Tier 1 CRDMO ranked world's 3rd-largest peptide CRDMO (after Bachem & PolyPeptide). 1,217 CRO and 332 CDMO projects completed. RMB 440M revenue in 2024 with HK IPO filed.
Ted Medicine (Tide Pharma) is based in Hangzhou, Zhejiang, China, specialising in CRDMO, CRO, CDMO, GLP-1 Pipeline, minimum order Contract-based.
No manufacturing licence is recorded for Ted Medicine (Tide Pharma) in our data. That is an absence of information rather than evidence of a problem, but it means nothing here has been verified against a regulator's register.
No independent assay in our records names Ted Medicine (Tide Pharma) as the manufacturer. Manufacturer attribution only appears where a certificate of analysis records it, so this is common and is not a quality signal in itself.
Manufacturer entries describe who produces a compound, not who sells it to you. For purchasing, the vendor directory records storefront reachability, assay history and FDA warning-letter history separately.
Directories: All manufacturers, Vendor directory, Independent lab tests.